Fostamatinib

Many traders are stepping away from the market in the last week of the year to celebrate the holiday season with friends and family. However, biotech traders know the market never takes a vacation. In fact, there are a number of major biotech catalysts expected out in the near future. Here’s...

BMO Capital's Do Kim initiated Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) at Outperform with a lofty $4.00 price target. Kim believes upcoming Phase III data in August may drive "significant upside to shares." The analyst was especially hopeful for the near-term data readout for lead drug...

The first Phase 3 trials for Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL)'s Syk inhibitor are expected to be announced in August as many investors and analysts prepare for the results. H.C. Wrainwright's Positive Take On Phase 3 H.C. Wainwright & Co's Shaunak Deepak initiated Rigel...